References
- Bieber T. 2008; Atopic dermatitis. N Engl J Med. 358:1483–94.
- Santamaria-Babi LF. 2006; Skin-homing T cells in cutaneous allergic inflammation. Chem Immunol Allergy. 91:87–97.
- Behnam SM, Behnam SE, Koo JY. 2005; Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol. 4:189–94.
- Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY. 1991; Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 338:137–40.
- Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, de Bruin-Weller MS. 2007; Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 21:85–9.
- Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R. 1997; SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation. 64:32–5.
- Kirchner GI, Meier-Wiedenbach I, Manns MP. 2004; Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 43:83–95.
- Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. 2001; Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. Br J Dermatol. 145:438–45.
- Frigerio E, Colombo MD, Franchi C, Altomare A, Garutti C, Altomare GF, 2007; Severe psoriasis treated with a new macrolide: Everolimus. Br J Dermatol. 156:372–4.
- Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A, 1997; Clinical validation and guidelines for the SCORAD index: Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 195:10–9.
- Krueger JG, Bowcock A. 2005; Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis. 64:(suppl 2)ii30–6.
- Lebwohl M. 2003; Psoriasis. Lancet. 361:1197–204.
- Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, 1999; A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 68:1100–6.